TScan Therapeutics, Inc. (TCRX)

USD 2.9

(-2.36%)

Market Cap (In USD)

154.77 Million

Revenue (In USD)

21.04 Million

Net Income (In USD)

-89.21 Million

Avg. Volume

352.89 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.6-9.69
PE
-
EPS
-
Beta Value
0.782
ISIN
US89854M1018
CUSIP
89854M101
CIK
1783328
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Gavin MacBeath Ph.D.
Employee Count
-
Website
https://www.tscan.com
Ipo Date
2021-07-16
Details
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.